4SC AG 2017 AR2
The report highlights 4SC's significant progress in 2017, including a successful capital increase raising gross ’41 million, which funds operations into 2020. The company advanced its clinical pipeline, recruiting over one-third of patients for the pivotal RESMAIN study of resminostat and initiating the Phase Ib/II SENSITIZE study of 4SC-202. Additionally, 4SC secured a U.S. patent for 4SC-208 and entered into new licensing agreements for non-core assets, such as Kv1.3 inhibitors with Maruho.
Company: 4SC AG
Sector: Manufacturing
Country: Germany
Year: 2017
Type: AR2
Pages: 88
Back to company
4SC AG
Annual Report
The report highlights 4SC's significant progress in 2017, including a successful capital increase raising gross ’41 million, which funds operations into 2020. The company advanced its clinical pipeline, recruiting over one-third of patients for the pivotal RESMAIN study of resminostat and initiating the Phase Ib/II SENSITIZE study of 4SC-202. Additionally, 4SC secured a U.S. patent for 4SC-208 and entered into new licensing agreements for non-core assets, such as Kv1.3 inhibitors with Maruho.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees